Treadwell Announces Initiation New Clinical Trial CFI 400945
Treadwell Announces Initiation of New Clinical Trial of CFI-400945 in Patients with Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Initiation Patient Dosing TWT 101 Phase
Treadwell Announces Initiation of Patient Dosing in TWT-101, a Phase 1/2 Study of HPK1 Inhibitor, CFI-402411, in Patients with Solid Tumors
Initiation Expansion Cohorts Ongoing Phase
Treadwell Announces Initiation of Expansion Cohorts in Ongoing Phase 1 Study of Oral TTK Inhibitor, CFI-402257, in Patients with Breast Cancer and Additional Solid Tumors
Initiation-Phase-2-Study-CFI-400945
Treadwell Announces Initiation of Phase 2 Study of CFI-400945 and Durvalumab in Patients with Advanced/Metastatic Triple Negative Breast Cancer (TNBC): IND.239
Treadwell-HPK1-inhibitor-IND-Approval
Treadwell Therapeutics Announces US FDA Clearance of IND Application for Phase 1/2 Study of HPK1 Inhibitor, CFI-402411
Jefferies Virtual Healthcare Conference
Jefferies 2020 Virtual Healthcare Conference
June 4, 2020 at 4:30 pm ET
